DS 4574

Drug Profile

DS 4574

Latest Information Update: 16 Feb 1995

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Antiulcers; Cytoprotectives; Small molecules
  • Mechanism of Action Leukotriene receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Peptic ulcer

Most Recent Events

  • 16 Feb 1995 Discontinued-II for Asthma in United Kingdom (PO)
  • 16 Feb 1995 Discontinued-II for Asthma in USA (PO)
  • 16 Feb 1995 Discontinued-II for Asthma in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top